Acadia Pharmaceuticals gets U.S. patent allowance for trofinetide dosing
The allowance covers weight-banded dosing of trofinetide for Rett syndrome and is expected to extend U.S. protection to March 28, 2041, from July 2036.
The allowance covers weight-banded dosing of trofinetide for Rett syndrome and is expected to extend U.S. protection to March 28, 2041, from July 2036.